Lipid Nutrition Gets New Insight into CLA
The outcomes of the new research give a good insight in the effects of Clarinol CLA since the research was conducted with a sufficient amount of people who need CLA for body weight management.
12/05/06 Loders Croklaan Lipid Nutrition has revealed its latest results on Clarinol CLA at a seminar at Vitafoods. New research shows that Clarinol CLA reduces fat mass in particular locations of the body, without any extra workout something that no other research was able to establish before. The subjects in the research lost 2 kg of fat (= equal to 8 packages of butter) around the waist area and in the legs.
The outcomes of the new research give a good insight in the effects of Clarinol CLA since the research was conducted with a sufficient amount of people who need CLA for body weight management. The population consisted of 118 overweight and obese persons (BMI 28-32 kg/m2) and was randomized into two groups: a CLA group and a placebo olive oil group for six months. Not only did the CLA group lose weight, but also lost a significantly amount of fat located in the legs and mid-section.
According to Dr. Sandra Einerhand, Director Nutrition & Toxicology at Lipid Nutrition this study proves that Clarinol CLA shapes the body. John Kurstjens, marketing manager at Lipid Nutrition is confident in the future developments of the CLA market. “We test and improve our products continuously. The fat loss that our product realises meets the highest standards of our clients. We are pleased to tell our clients that Clarinol CLA is the better ingredient for an even more effective product.”
In the CLA supplemented group reduction of the fat mass was already observed after three months. The women in the CLA group showed a reduction located in the legs and trunk whereas for men the reduction was mainly in the trunk. No research was able to establish that before. Overall body weight, hip/waist ratio and BMI reduced relatively to placebo.
Additionally, the safety of Clarinol CLA was evaluated by monitoring adverse events and blood safety parameters. Insulin sensitivity was not adversely affected. All participants tolerated Clarinol CLA well.
